bluebird bio, Inc. (Nasdaq: BLUE) announces that management will present
at the Wedbush Securities Life Sciences Conference to be held August 13
- 14, 2013 at the Le Parker Meridien Hotel, New York, NY, and at the
Canaccord Genuity Healthcare Conference to be held August 14 - 15, 2013
at the Intercontinental Hotel, Boston, MA. Nick Leschly, Chief bluebird,
will provide an overview of the company at the Wedbush Conference on
Tuesday, August 13, 2013 at 1:20 PM (ET) and at the Canaccord Genuity
Conference on Thursday, August 15, 2013 at 8:00 AM (ET).
To access a simultaneous webcast of Mr. Leschly's overview via the
internet, log on to the "Calendar of Events" section on the Investor and
Media page of the bluebird bio's website at http://investor.bluebirdbio.com.
Please connect to the website at least ten minutes prior to the start of
the presentation to ensure adequate time for a reliable connection and
any software download that may be necessary for the webcast.
A replay of the webcasts will be available on bluebird bio's website for
ninety days following the conference. The investor presentation will be
available for download in PDF format immediately following the
presentation in the "Calendar of Events" section of the Investor and
Media page of the bluebird bio's website at http://investor.bluebirdbio.com.
About bluebird bio, Inc.
bluebird bio is a clinical-stage company committed to developing
potentially transformative gene therapies for severe genetic and orphan
diseases. bluebird bio has two clinical-stage programs in development.
The most advanced product candidate, Lenti-D, is expected to enter a
phase 2/3 study in late 2013 for the treatment of childhood cerebral
adrenoleukodystrophy (CCALD), a rare, hereditary neurological disorder
affecting young boys. The next most advanced product candidate,
LentiGlobin, is currently in a phase 1/2 study in France for the
treatment of beta-thalassemia major and severe sickle cell disease. A
second phase 1/2 study with LentiGlobin is expected to initiate in the
United States in mid- 2013 for the treatment of beta-thalassemia major.
bluebird bio also has an early stage chimeric antigen receptor modified
T cell (CAR-T) program for oncology in partnership with Celgene
Corporation. bluebird bio has operations in Cambridge, Massachusetts,
San Francisco, California and Paris, France. For more information,
please visit www.bluebirdbio.com.
Forward-Looking Statements
This release contains “forward-looking statements” within the meaning
of the Private Securities Litigation Reform Act of 1995, including
statements regarding the advancement of our clinical trials. Any
forward-looking statements in this press release are based on
management's current expectations of future events and are subject to a
number of risks and uncertainties that could cause actual results to
differ materially and adversely from those set forth in or implied by
such forward-looking statements. These risks and uncertainties
include, but are not limited to, the risk of cessation or delay of any
of the ongoing or planned clinical trials and/or our development of our
product candidates, the risk that the results of previously conducted
studies involving similar product candidates will not be repeated or
observed in ongoing or future studies involving current product
candidates, the risk that our collaboration with Celgene will not
continue or will not be successful, and the risk that any one or more of
our product candidates will not be successfully developed and
commercialized. For a discussion of other risks and uncertainties, and
other important factors, any of which could cause our actual results to
differ from those contained in the forward-looking statements, see the
section entitled "Risk Factors" in the final prospectus related to our
initial public offering filed with the Securities and Exchange
Commission pursuant to Rule 424(b) of the Securities Act, as well as
discussions of potential risks, uncertainties, and other important
factors in our subsequent filings with the Securities and Exchange
Commission. All information in this press release is as of the
date of the release, and bluebird bio undertakes no duty to update this
information unless required by law.
Copyright Business Wire 2013